Emerging Novel Agents for Patients with Advanced Ewing Sarcoma: a Report from the Children's Oncology Group (COG) New Agents for Ewing Sarcoma Task Force

Overview

Journal F1000Res

Specialties Biomedical Engineering
Science

Date 2019 Apr 30

PMID 31031965

Citations 38

Authors

Kelly Bailey

Carrye Cost

Ian Davis

Julia Glade-Bender

Patrick Grohar

Peter Houghton

Michael Isakoff

Elizabeth Stewart

Nadia Laack

Jason Yustein

Damon Reed

Katherine Janeway

Richard Gorlick

Stephen Lessnick

Steven Dubois

Pooja Hingorani

Affiliations

Soon will be listed here.

Abstract

Ewing sarcoma is a small round blue cell malignancy arising from bone or soft tissue and most commonly affects adolescents and young adults. Metastatic and relapsed Ewing sarcoma have poor outcomes and recurrences remain common. Owing to the poor outcomes associated with advanced disease and the need for a clear research strategy, the Children's Oncology Group Bone Tumor Committee formed the New Agents for Ewing Sarcoma Task Force to bring together experts in the field to evaluate and prioritize new agents for incorporation into clinical trials. This group's mission was to evaluate scientific and clinical challenges in moving new agents forward and to recommend agents and trial designs to the Bone Tumor Committee. The task force generated a framework for vetting prospective agents that included critical evaluation of each drug by using both clinical and non-clinical parameters. Representative appraisal of agents of highest priority, including eribulin, dinutuximab, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, anti-angiogenic tyrosine kinase inhibitors, and poly-ADP-ribose polymerase (PARP) inhibitors, is described. The task force continues to analyze new compounds by using the paradigm established.

Citing Articles

A Bayesian active learning platform for scalable combination drug screens.

Tosh C, Tec M, White J, Quinn J, Ibanez Sanchez G, Calder P Nat Commun. 2025; 16(1):156.

PMID: 39746987 PMC: 11696745. DOI: 10.1038/s41467-024-55287-7.

Prospects of anti-GD2 immunotherapy for retinoblastoma.

Zhang X, You W, Wang Y, Dejenie R, Wang C, Huang Y Front Immunol. 2024; 15:1499700.

PMID: 39620227 PMC: 11604707. DOI: 10.3389/fimmu.2024.1499700.

UK guidelines for the management of bone sarcomas.

Gerrand C, Amary F, Anwar H, Brennan B, Dileo P, Kalkat M Br J Cancer. 2024; 132(1):32-48.

PMID: 39550489 PMC: 11723950. DOI: 10.1038/s41416-024-02868-4.

MERTK Is a Potential Therapeutic Target in Ewing Sarcoma.

Smart S, Yeung T, Santos M, McSwain L, Wang X, Frye S Cancers (Basel). 2024; 16(16).

PMID: 39199601 PMC: 11352666. DOI: 10.3390/cancers16162831.

Cadherin-11 contributes to the heterogenous and dynamic Wnt-Wnt-β-catenin pathway activation in Ewing sarcoma.

Shirai R, Biebighauser T, Walker D, Oviedo J, Nelson-Taylor S, Bodlak A PLoS One. 2024; 19(6):e0305490.

PMID: 38875295 PMC: 11178195. DOI: 10.1371/journal.pone.0305490.

References

Ladenstein R, Potschger U, Cecile Le Deley M, Whelan J, Paulussen M, Oberlin O . Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol. 2010; 28(20):3284-91. DOI: 10.1200/JCO.2009.22.9864. View

Okouneva T, Azarenko O, Wilson L, Littlefield B, Jordan M . Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther. 2008; 7(7):2003-11. PMC: 2562299. DOI: 10.1158/1535-7163.MCT-08-0095. View

Chuk M, Widemann B, Minard C, Liu X, Kim A, Bernhardt M . A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group. Pediatr Blood Cancer. 2018; 65(8):e27077. PMC: 6082380. DOI: 10.1002/pbc.27077. View

Iniguez A, Stolte B, Wang E, Conway A, Alexe G, Dharia N . EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma. Cancer Cell. 2018; 33(2):202-216.e6. PMC: 5846483. DOI: 10.1016/j.ccell.2017.12.009. View

Serrano M, Hannon G, Beach D . A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993; 366(6456):704-7. DOI: 10.1038/366704a0. View

Attia S, Okuno S, Robinson S, Webber N, Indelicato D, Bagaria S . Clinical Activity of Pazopanib in Metastatic Extraosseous Ewing Sarcoma. Rare Tumors. 2015; 7(2):5992. PMC: 4508650. DOI: 10.4081/rt.2015.5992. View

Hu-Lieskovan S, Zhang J, Wu L, Shimada H, Schofield D, Triche T . EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing's family of tumors. Cancer Res. 2005; 65(11):4633-44. DOI: 10.1158/0008-5472.CAN-04-2857. View

Smith M, Reynolds C, Kang M, Kolb E, Gorlick R, Carol H . Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program. Clin Cancer Res. 2014; 21(4):819-32. PMC: 4587665. DOI: 10.1158/1078-0432.CCR-14-2572. View

Dobrenkov K, Ostrovnaya I, Gu J, Cheung I, Cheung N . Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults. Pediatr Blood Cancer. 2016; 63(10):1780-5. PMC: 5215083. DOI: 10.1002/pbc.26097. View

10.

Newlands E, Blackledge G, Slack J, Rustin G, Smith D, Stuart N . Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer. 1992; 65(2):287-91. PMC: 1977719. DOI: 10.1038/bjc.1992.57. View

11.

Fisher J, Flutter B, Wesemann F, Frosch J, Rossig C, Gustafsson K . Effective combination treatment of GD2-expressing neuroblastoma and Ewing's sarcoma using anti-GD2 ch14.18/CHO antibody with Vγ9Vδ2+ γδT cells. Oncoimmunology. 2016; 5(1):e1025194. PMC: 4760299. DOI: 10.1080/2162402X.2015.1025194. View

12.

Tawbi H, Burgess M, Bolejack V, Van Tine B, Schuetze S, Hu J . Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017; 18(11):1493-1501. PMC: 7939029. DOI: 10.1016/S1470-2045(17)30624-1. View

13.

Kuznetsov G, Towle M, Cheng H, Kawamura T, TenDyke K, Liu D . Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res. 2004; 64(16):5760-6. DOI: 10.1158/0008-5472.CAN-04-1169. View

14.

Lerman D, Monument M, McIlvaine E, Liu X, Huang D, Monovich L . Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2014; 62(5):759-65. PMC: 4376595. DOI: 10.1002/pbc.25340. View

15.

Langenau D, Sweet-Cordero A, Wechsler-Reya R, Dyer M . Preclinical Models Provide Scientific Justification and Translational Relevance for Moving Novel Therapeutics into Clinical Trials for Pediatric Cancer. Cancer Res. 2015; 75(24):5176-5186. PMC: 4681628. DOI: 10.1158/0008-5472.CAN-15-1308. View

16.

Pedersen E, Menon R, Bailey K, Thomas D, Van Noord R, Tran J . Activation of Wnt/β-Catenin in Ewing Sarcoma Cells Antagonizes EWS/ETS Function and Promotes Phenotypic Transition to More Metastatic Cell States. Cancer Res. 2016; 76(17):5040-53. PMC: 5010452. DOI: 10.1158/0008-5472.CAN-15-3422. View

17.

Harlow M, Chasse M, Boguslawski E, Sorensen K, Gedminas J, Kitchen-Goosen S . Trabectedin Inhibits EWS-FLI1 and Evicts SWI/SNF from Chromatin in a Schedule-dependent Manner. Clin Cancer Res. 2019; 25(11):3417-3429. PMC: 6594545. DOI: 10.1158/1078-0432.CCR-18-3511. View

18.

Dubois S, Marina N, Glade-Bender J . Angiogenesis and vascular targeting in Ewing sarcoma: a review of preclinical and clinical data. Cancer. 2009; 116(3):749-57. PMC: 2815027. DOI: 10.1002/cncr.24844. View

19.

Bernstein M, Devidas M, Lafreniere D, Souid A, Meyers P, Gebhardt M . Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457--a report from the Children's Oncology Group. J Clin Oncol. 2005; 24(1):152-9. DOI: 10.1200/JCO.2005.02.1717. View

20.

Brenner J, Feng F, Han S, Patel S, Goyal S, Bou-Maroun L . PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. Cancer Res. 2012; 72(7):1608-13. PMC: 3319786. DOI: 10.1158/0008-5472.CAN-11-3648. View